Literature DB >> 25899862

Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.

Partow Kebriaei1, Michelle Limei Poon.   

Abstract

The prognosis of acute lymphoblastic leukemia (ALL) in adults remains poor, and novel treatment options are needed to improve outcomes. Immunotherapeutic strategies have been a recent focus in this area, targeting specific surface antigens on the ALL blast cells. Our review concentrates on four major class of antibody therapies, namely, (1) naked and unconjugated antibodies, (2) immunoconjugates and immunotoxins, (3) bi-specific T cell engaging (BiTE) therapy, and (4) chimeric antigen receptor (CAR) expressing T cells. We review preclinical and clinical data, and update on the latest advances in this exciting field, and suggest how these therapies can be incorporated into the treatment algorithm for ALL.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25899862     DOI： 10.1007/s11899-015-0251-8

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  40 in total

Review 1.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

2.  A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.

Authors:  John Schindler; Srikanth Gajavelli; Farhad Ravandi; Yumin Shen; Samir Parekh; Ira Braunchweig; Stefan Barta; Victor Ghetie; Ellen Vitetta; Amit Verma
Journal:  Br J Haematol       Date:  2011-07-07       Impact factor: 6.998

3.  Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.

Authors:  Francis Mussai; Dario Campana; Deepa Bhojwani; Maryalice Stetler-Stevenson; Seth M Steinberg; Alan S Wayne; Ira Pastan
Journal:  Br J Haematol       Date:  2010-06-07       Impact factor: 6.998

4.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

5.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

6.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

Authors:  Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebriaei; Michael Rytting; Sergernne York; Farhad Ravandi; Monica Kwari; Stefan Faderl; Mary Beth Rios; Jorge Cortes; Luis Fayad; Robert Tarnai; Sa A Wang; Richard Champlin; Anjali Advani; Susan O'Brien
Journal:  Lancet Oncol       Date:  2012-02-21       Impact factor: 41.316

7.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

8.  Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Authors:  Sébastien Maury; Françoise Huguet; Thibaut Leguay; Francis Lacombe; Marc Maynadié; Sandrine Girard; Adrienne de Labarthe; Emilienne Kuhlein; Emmanuel Raffoux; Xavier Thomas; Patrice Chevallier; Agnès Buzyn; André Delannoy; Yves Chalandon; Jean-Paul Vernant; Philippe Rousselot; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Marie-Christine Béné
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

9.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.

Authors:  Anjali S Advani; Shannon McDonough; Steven Coutre; Brent Wood; Jerald Radich; Martha Mims; Margaret O'Donnell; Stephanie Elkins; Michael Becker; Megan Othus; Frederick R Appelbaum
Journal:  Br J Haematol       Date:  2014-03-03       Impact factor: 6.998

10.  Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.

Authors:  Xavier Thomas; Jean-Michel Boiron; Françoise Huguet; Hervé Dombret; Ken Bradstock; Norbert Vey; Tibor Kovacsovics; André Delannoy; Nathalie Fegueux; Pierre Fenaux; Aspasia Stamatoullas; Jean-Paul Vernant; Olivier Tournilhac; Agnès Buzyn; Oumedaly Reman; Christiane Charrin; Claude Boucheix; Jean Gabert; Véronique Lhéritier; Denis Fiere
Journal:  J Clin Oncol       Date:  2004-09-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.